The trial realized both its Main endpoints, with semaglutide two.four mg demonstrating statistically sizeable and top-quality enhancements in liver fibrosis without any worsening of steatohepatitis, as well as resolution of steatohepatitis without worsening of liver fibrosis in individuals with MASH